Navigation Links
Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
Date:4/22/2008

- Strong Sales Growth Across All Product Lines

- Transcatheter Valves Propel Heart Valve Sales Growth

- Special Items Reduce Net Income by $15 Million

IRVINE, Calif., April 22 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today reported net income for the quarter ended March 31, 2008 of $18.2 million, or $0.31 per diluted share, compared to net income of $33.2 million, or $0.54 per diluted share for the same period in 2007. Excluding special items from this year detailed in the reconciliation table below, first quarter 2008 net income was $33.2 million, or $0.56 per diluted share.

First quarter net sales increased 12.4 percent to $296.8 million, compared to $264.1 million in the same quarter last year. Underlying sales growth was 9.0 percent, excluding the impact of $4.1 million of sales from discontinued products and a $13.0 million contribution from foreign exchange.

"We're very pleased to report strong first quarter results, driven by robust sales growth in all of our product lines," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "In addition, we are raising our full year 2008 sales guidance by $50 million and increasing our bottom-line expectations.

"This quarter was also highlighted by an impressive start to our Edwards SAPIEN transcatheter heart valve launch in Europe, with better than expected sales of $8.1 million and outstanding procedural success." Sales Results

For the first quarter, the company reported Heart Valve Therapy sales of $146.7 million, a 13.3 percent increase over prior year, which included a $6.1 million positive
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
2. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
3. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
4. Edwards Lifesciences Announces Organizational Changes
5. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
7. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
8. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., LIBREVILLE, Gabon, December 2 /PRNewswire/ -... Everyone,s Problem and Heritage" , Coinc... 2-3 June 2010 the,Gabonese Republic is hosting an... the issue of safeguarding biological resources in...ment and state leaders, ministers,scientific expe...
(Date:12/2/2009)... , CAMBRIDGE, Mass., Dec. 2 Te...aders in technology development and product integr...nounced the December 11th deadline for technology ... its 14th year, TechConnect World, in association ...TI), and the Clean Technology and Sustainable Indu...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)..., NANJING, China, Dec. 2 /PRNewswire-Asia/ -...Company") (NYSE: SCR ), a leading pharmaceutical...uring, and marketing of branded,generic and propri...at 105 of,its drugs have been included in China,s ...as issued by China,s Ministry of Human Resources a...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., R.I., May 28 Neurotech Pharmaceuticals, Inc. to..., NT-501, demonstrated a strong biologic effect ...ntosa (RP). RP is a slowly developing condition ...mp; cone photoreceptor cells in the retina that ov... eventually leads to blindness. RP is an orphan-de...
...NS, France, May 28 Poxel is a research integrated...ck Serono a division of,Merck KGaA, Germany, follo...est in diabetes research and development. It aims ...iseases (with a primary focus on Type 2,diabetes) ..., before,out-licensing these projects to major pha...
...rovides way of integrating and sustaining positive...28 In today,s uncertain times, increased stress c...rging wellness, growth and behavioral change parad...make healthier lifestyle choices and enjoy increas...llenges. , , The approach, called Reorganizationa...
Other Biology Technology:Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2
(Date:12/3/2009)...ies can be likened to emptying a museum of its col...dicines into the trash, or replacing every local c...e of species and their habitats may not just make ... also put you at greater risk for catching some na...sity loss,"driven by the replacement of local spec...
(Date:12/3/2009)... CTRC-AACR San Antonio Breast Cancer Symposium con...e and world leaders from industry and academia wit... year, more than 8,500 scientists and other profes...ntion Center in San Antonio from Dec. 9-13, 2009. ...n Association for Cancer Research, the University ...
(Date:12/3/2009)...ty change in warmer water, according to an intrigu...ake some species more aggressive. , Experiments ...s Great Barrier Reef have shown for the first time..., or consistently bold, and that these individual ...ures rise. , A slight lift of just one or two de...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Fish with attitude: Some like it hot 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Growth Attracts Additional Investors to Sittercity com 55841 1Growth Attracts Additional Investors to Sittercity com 55841 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2
...tin has received a six-year contract from the U.S....rt for the AN/UYQ-70 (Q-70) Advanced Display Syste... support at over $13 million a year for the first ...r the next four years, bringing the total potentia...t follows a recently awarded $525.6 million modifi...
...s March 19 during 12 p.m. Advertising Research Fou...e Research (R), a revolutionary media research fir... Advertising Research Foundation (ARF) conference ...identified key themes and styles that comprise imp...which were captured and delivered during the ARF,s...
...niversity of Florida have introduced ,Delicious, a...early, produces high yields, and is disease-resist...d texture with an edible skin, making it well-suit...or wine production. The name ,Delicious, was selec... sampled the fruit., According to Dr. Dennis J. Gr...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
MitoPT-25:MITOCHONDRIAL PERMEABILITY TRANSITION KIT from AbD Serotec
Rabbit Anti-Human DDX5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Human phospho-RTKs Antibody array Assay Kit from R&D Systems
Human Antibody Array I Kit, RayBio L Series 507: RayBio Label-based from Raybiotech, Inc.
Biology Products: